[{"indications": "Indications\u00a0major depression, generalised anxiety disorder", "name": "VENLAFAXINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.3 Antidepressant drugs", "4.3.4 Other antidepressant drugs"], "cautions": "Cautions\u00a0heart disease (monitor\r\nblood pressure); diabetes; history of epilepsy; history or family history\r\nof mania; susceptibility to angle-closure glaucoma; concomitant use of drugs that increase risk of bleeding, history of bleeding disorders; interactions: Appendix 1 (venlafaxine)Driving\u00a0May affect performance of\r\nskilled tasks (e.g. driving)Withdrawal\u00a0Gastro-intestinal disturbances, headache,\r\nanxiety, dizziness, paraesthesia, tremor, sleep disturbances, and\r\nsweating are most common features of withdrawal if treatment stopped\r\nabruptly or if dose reduced markedly; dose should be reduced over\r\nseveral weeks", "side-effects": "Side-effects\u00a0constipation, nausea, anorexia, weight changes,\r\nvomiting; hypertension, palpitation, vasodilatation, changes in serum\r\ncholesterol; chills, yawning; dizziness, dry mouth, insomnia, nervousness,\r\ndrowsiness, asthenia, headache, abnormal dreams, anxiety, confusion,\r\nhypertonia, sensory disturbances, tremor; difficulty with micturition,\r\nsexual dysfunction, menstrual disturbances; visual disturbances, mydriasis\r\n(very rarely angle-closure glaucoma); sweating; less commonly bruxism, diarrhoea, taste disturbance, postural\r\nhypotension, arrhythmias, agitation, apathy, incoordination, hallucinations,\r\nmyoclonus, angioedema, urinary retention, bleeding disorders (including\r\necchymosis and gastro-intestinal haemorrhage), tinnitus, alopecia,\r\nphotosensitivity, and rash; rarely mania, hypomania,\r\nseizures, extrapyramidal symptoms including akathisia, urinary incontinence; also reported hepatitis, pancreatitis, hypotension, QT-interval\r\nprolongation, aggression, neuroleptic malignant syndrome, delirium,\r\nvertigo, syndrome of inappropriate anti-diuretic hormone secretion\r\n(see Hyponatraemia and Antidepressant\r\nTherapy),\r\nhyperprolactinaemia, blood dyscrasias, rhabdomyolysis, pruritus, urticaria,\r\nStevens-Johnson syndrome; suicidal behaviour (see Suicidal Behaviour and Antidepressant\r\nTherapy)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/27102.htm", "doses": ["Depression, adult over\r\n18 years, initially 75\u00a0mg daily in 2 divided doses increased if necessary\r\nat intervals of at least 2 weeks; max. 375\u00a0mg daily; child under 18 years not recommended (see Depressive Illness in Children\r\nand Adolescents)", "Faster dose titration may be necessary in\r\nsome patients", "Generalised anxiety disorder and social anxiety disorder, see\r\nunder preparations below"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk\u2014toxicity\r\nin animal studies; risk of withdrawal effects in\r\nneonate"}, {"indications": "Indications\u00a0major depression, generalised anxiety disorder", "name": "VENLAFAXINE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.3 Antidepressant drugs", "4.3.4 Other antidepressant drugs", "VENLAFAXINE", "Modified release"], "cautions": "Cautions\u00a0heart disease (monitor\r\nblood pressure); diabetes; history of epilepsy; history or family history\r\nof mania; susceptibility to angle-closure glaucoma; concomitant use of drugs that increase risk of bleeding, history of bleeding disorders; interactions: Appendix 1 (venlafaxine)Driving\u00a0May affect performance of\r\nskilled tasks (e.g. driving)Withdrawal\u00a0Gastro-intestinal disturbances, headache,\r\nanxiety, dizziness, paraesthesia, tremor, sleep disturbances, and\r\nsweating are most common features of withdrawal if treatment stopped\r\nabruptly or if dose reduced markedly; dose should be reduced over\r\nseveral weeks", "side-effects": "Side-effects\u00a0constipation, nausea, anorexia, weight changes,\r\nvomiting; hypertension, palpitation, vasodilatation, changes in serum\r\ncholesterol; chills, yawning; dizziness, dry mouth, insomnia, nervousness,\r\ndrowsiness, asthenia, headache, abnormal dreams, anxiety, confusion,\r\nhypertonia, sensory disturbances, tremor; difficulty with micturition,\r\nsexual dysfunction, menstrual disturbances; visual disturbances, mydriasis\r\n(very rarely angle-closure glaucoma); sweating; less commonly bruxism, diarrhoea, taste disturbance, postural\r\nhypotension, arrhythmias, agitation, apathy, incoordination, hallucinations,\r\nmyoclonus, angioedema, urinary retention, bleeding disorders (including\r\necchymosis and gastro-intestinal haemorrhage), tinnitus, alopecia,\r\nphotosensitivity, and rash; rarely mania, hypomania,\r\nseizures, extrapyramidal symptoms including akathisia, urinary incontinence; also reported hepatitis, pancreatitis, hypotension, QT-interval\r\nprolongation, aggression, neuroleptic malignant syndrome, delirium,\r\nvertigo, syndrome of inappropriate anti-diuretic hormone secretion\r\n(see Hyponatraemia and Antidepressant\r\nTherapy),\r\nhyperprolactinaemia, blood dyscrasias, rhabdomyolysis, pruritus, urticaria,\r\nStevens-Johnson syndrome; suicidal behaviour (see Suicidal Behaviour and Antidepressant\r\nTherapy)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/208497.htm", "doses": ["Depression, adult over\r\n18 years, initially 75\u00a0mg daily in 2 divided doses increased if necessary\r\nat intervals of at least 2 weeks; max. 375\u00a0mg daily; child under 18 years not recommended (see Depressive Illness in Children\r\nand Adolescents)", "Generalised anxiety disorder and social anxiety disorder, see\r\nunder preparations below", "Faster dose titration may be necessary in\r\nsome patients", "Faster dose titration may be necessary in\r\nsome patients", "Name[Venlafaxine m/r preparations ] Capsules, m/r, venlafaxine (as hydrochloride)\r\n75\u00a0mg; 150\u00a0mg. \r\n    Label:\r\n    3, 25, counselling, drivingBrands include Alventa XL\u00ae, Bonilux XL\u00ae, Depefex\u00ae XL, Foraven XL\u00ae, Politid XL\u00ae, Ranfaxine XL\u00ae, Tifaxin XL\u00ae, Venaxx XL\u00ae, Vensir XL\u00ae, Winfex\u00ae XLDose\u00a0depression, adult over\r\n18 years, 75\u00a0mg once daily, increased if necessary at intervals of\r\nat least 2 weeks; max. 375\u00a0mg once daily; child under 18 years not recommended (see Depressive Illness in Children\r\nand Adolescents)Note\u00a0Faster dose titration may be necessary in\r\nsome patientsGeneralised anxiety disorder, adult over 18 years, 75\u00a0mg once daily, increased if necessary at intervals\r\nof at least 2 weeks; max. 225\u00a0mg once dailySocial anxiety disorder, adult over 18 years, recommended dose 75\u00a0mg once daily (no evidence of\r\ngreater efficacy at higher doses); dose may be increased at intervals\r\nof at least 2 weeks; max. 225\u00a0mg once daily\nTablets, m/r, venlafaxine (as hydrochloride)\r\n37.5\u00a0mg; 75\u00a0mg; 150\u00a0mg; 225\u00a0mg. \r\n    Label:\r\n    3, 25, counselling, drivingBrands include Venlalic\u00ae XLDose\u00a0depression, adult over\r\n18 years, 75\u00a0mg once daily, increased if necessary at intervals of\r\nat least 2 weeks; max. 375\u00a0mg once daily; child under 18 years not recommended (see Depressive Illness in Children\r\nand Adolescents)Note\u00a0Faster dose titration may be necessary in\r\nsome patients"], "pregnancy": "Pregnancy\u00a0avoid unless potential benefit outweighs risk\u2014toxicity\r\nin animal studies; risk of withdrawal effects in\r\nneonate"}]